Table 4.
Pharmacokinetic parameters from cats after treatment with subcutaneous buprenorphine at 0.02, 0.06, 0.12 and 0.24 mg/kg body weight and using formulations containing 0.3, 0.6 and 1.2 mg/kg with and without preservatives
| Buprenorphine | |||||
|---|---|---|---|---|---|
| Group dose (formulation ID)* | Cmax (ng/ml) † | Tmax (h) † | AUC ng/ml/h ‡ | k(el)/h † | Ratio norbuprenorphine/ buprenorphine † |
| AG6 0.02 mg/kg (standard/low) (A) | 1.3 (1.0–1.7) | 0.42 (0.25–0.50) | 6.43 ± 3.90 | 0.37570 (0.1300–0.5144) | 0 |
| AG4 0.06 mg/kg (medium) (D) | 3.4 (1.4–4.9) | 0.70 (0.25–2.00) | 61.8 ± 13.2 | 0.0324 (0.0222–0.0431) | – |
| AG2 0.12 mg/kg (high) (A) | 6.5 (5.7–7.7) | 0.75 (0.5–1.00) | 115.6 ± 32.1 | 0.03394 (0.0221–0.0471) | 0.45 (0.17–0.34) |
| AG3 0.12 mg/kg (high) (C) | 20.8 (4.5–51.4) | 0.67 (0.50–1.00) | 163.55 ± 64.40 | 0.04152 (0.0310–0.05063) | 0.5 (0.21–0.99) |
| AG3 0.12 mg/kg (high) (D) | 10.3 (6.1–22.6) | 0.7 (0.5–1.0) | 139.6 ± 11.7 | 0.0371 (0.0204–0.0584) | – |
| AG7 0.12 mg/kg (high) (B) | 14.9 (6.6–29.5) | 0.83 (0.50–1.00) | 160.74 ± 19.80 | 0.04851 (0.0348–0.0688) | 0.32 (0.21–0.53) |
| AG5 0.24 mg/kg (very high) (D) | 15.6 (5.3–22.4) | 0.63 (0.25–1.00) | 265.07 ± 53.60 | 0.04206 (0.0302–0.0497) | 0.40 (0.18–0.61) |
*
See footnote to Table 1 for formulation IDs
†
Mean (range)
‡
Mean ± SD
Cmax = peak concentration; Tmax = time to peak concentration; AUC = area under the concentration time curve